Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2023
Filed with the SEC on Mar 28, 2024 and accepted by EDGAR at Mar 28, 2024, 09:30 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-01-01 to 2023-12-31 | $6.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$8.2m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$7.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 1,278,333,912 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$8.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $2.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-12-31 | $4.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $9.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $10.0m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $2.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2023-12-31 | $6.2m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-12-31 | 1,359,837,393 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-24-026947. Last ingested by Listed: Nov 9, 2026, 17:23 ET. Listed shows no prices and gives no investment advice.